Vaccine

Details Vaccine Vaccine

2005-12-16

2010-12-28

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

Reexamination Certificate

active

07858098

ABSTRACT:
This invention pertains to methods for treating infections caused by human papillomaviruses. It has been determined that immunization with HPV16 and HPV 18 virus like particles provides cross-protection against other HPV types.

REFERENCES:
patent: 5855891 (1999-01-01), Lowy et al.
patent: 6066324 (2000-05-01), Gissmann et al.
patent: 6245568 (2001-06-01), Volkin et al.
patent: 6251678 (2001-06-01), Volkin et al.
patent: 6908613 (2005-06-01), Wilson et al.
patent: 6936255 (2005-08-01), Wettendorff
patent: 7101560 (2006-09-01), Wettendorff
patent: 7217419 (2007-05-01), Wettendorff
patent: 7416846 (2008-08-01), Wettendorff
patent: 2004/0121465 (2004-06-01), Robinson
patent: 2006/0177817 (2006-08-01), Jansen et al.
patent: 2006/0240040 (2006-10-01), Bryan et al.
patent: 2007/0036824 (2007-02-01), Bryan et al.
patent: 2008/0226660 (2008-09-01), Bryan et al.
patent: WO 94/21292 (1994-09-01), None
patent: WO 95/17209 (1995-06-01), None
patent: WO 95/31532 (1995-11-01), None
patent: WO 96/11274 (1996-04-01), None
patent: WO 99/45957 (1999-09-01), None
patent: WO 99/50424 (1999-10-01), None
patent: WO 00/09699 (2000-02-01), None
patent: WO 00/23105 (2000-04-01), None
patent: WO 01/17550 (2001-03-01), None
patent: WO01/97840 (2001-12-01), None
patent: WO03/077942 (2003-09-01), None
patent: WO 2004/056389 (2004-07-01), None
patent: WO2005/032586 (2005-04-01), None
Almadori et al (Clinical Cancer Research 7:3988-3993, 2001).
Smith et al (International Journal of Cancer 108:766-772, 2004).
Koutsky et al (New England Journal of Medicine 347: 1645-1651, 2002).
Suzich et al ( Proceedings of the National Academy of Sciences USA 92:11553-11557, 1995).
Moore et al (Journal of General Virology 83: 229902301, 2002).
Zhehbe et al (Journal of Pathology 181:270-274, 1997).
Giroglou et al., “Immunological Analyses of Human Papillomavirus Capsids”,Vaccine, Butterworth Scientific, vol. 19, No. 13-14, pp. 1783-1793 (2001).
Clifford, et al., “Human Papillomavirus Types in Invasive Cervical Cancer Worldwide: A Meta-Analysis”,British Journal of Cancer, vol. 88, pp. 63-73 (2003).
Munoz, et al., “Against Which Human Papillomavirus Types Shall We Vaccinate and Screen? The International Perspective”,Int. J. Cancer, vol. 111, 278-285 (2004).
Bachtiary, et al, Impact of multiple HPV infection on response to treatment and survival in pts. receiving radical radiotherapy for cervical cancer, International Journal of Cancer, Journal International Du Cancer, US, Nov. 20, 2002, vol. 102, No. 3, pp. 237-243.
Balsley, J.F., et al, Progress in the development of human papillomavirus vaccines for HPV-11 and HPV-16/18 and mapping of a critical neutralizing epitope, 18thInternational Papillomavirus Conference 2000, Online 2000, XP002278802, Retrieved from Internet: www.hpv2000.com/idabstract.asp, retrieved on May 3, 2004.
Bass, et al, Progress in the search of a vaccine against human papilloma virus, IAVI Report Oct./Nov. 2002, Online, Oct. 10, 2002, retrieved from the Internet—www.aegis.com/pubs/iavi/2002/IAVI2002-1003.html, retrieved on Apr. 21, 2004.
Billich A, “HPV Vaccine Medimmune/ GlaxoSmithKline”, Current Opinion in Invest. Drugs, vol. 4, No. 2, Feb. 2003, pp. 210-213.
Bosch, et al., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective, J. Nat. Canc. Inst. vol. 87, No. 11, pp. 796-802 (1995).
Breitburd et al., Immunization with Virus-Like Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect Against Experimental CRPV Infection, Journal of Virology, vol. 69, p. 3959-3963(1995).
Brown, et al, A dose ranging study of the safety and immunogenicity profiles of a quadrivalent HPV (types 6, 11, 16 and 18) Ll VLP candidate vaccine in young healthy women, Abstract 0-51, 19thInternational Papillomavirus Conference, Sep. 2001, Florianopolis, Brazil.
Carter, et al., Comparison of human papillomavirus Types 16, 18, and 6 capsid antibody responses following incident infection, The Journal of Infectious Diseases Society of America, vol. 181, pp. 19111-19119 (2000).
Chan, et al., Analysis of genomic sequences of 95 papillomavirus types: Uniting typing, phylogeny, and taxonomy, Journal of Virology, vol. 69, No. 5, pp. 3074-3083 (1995).
Chan, et al., Phylogenetic analysis of 48 papillomavirus types and 28 subtypes and variants: a showcase for the molecular evolution of DNA viruses, J. Virology, vol. 66, No. 10, pp. 5714-5725 (1992).
Christensen, N. D., et al., Monoclonal Antibodies to HPV-6 L1 Virus-Like Particles Identify Comformational and Linear Neutralizing Epitopes on HIV-11 in Addition to Type-Specific Epitopes on HPV-6, Virology, 1996, vol. 224, pp. 477-486.
Clifford, et al, Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis, British J. of Cancer, vol. 89, pp. 101-105 (2003).
Clifford, et al., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis, British J. of Cancer, vol. 88, pp. 63-73 (2003).
Combita, Alba-Lucia, et al, Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses, Journal of Virology, US, vol. 76, No. 13, Jul. 2002, pp. 6480-6486.
DeVilliers, E.M., et al: “Classification of Papillomaviruses,” Virology, Academic Press, Orlando, cited in the application (the whole document), US, vol. 324, No. 1, Jun. 20, 2004, pp. 17-27.
Giroglou et al , “Immunological analyses of human papillomavirus capsids”, Vaccine, vol. 19, No. 13-14, 2001, pp. 1783-1793 (2001).
GlaxoSmithKline HPV Vaccine Study Group, Harper et al., “Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection with Human Papillomavirus Types 16 and 18 in Young Women: A Rand. Contr. Trial”, The Lancet (Limited), vol. 364, No. 9447, Nov. 13, 2004, pp. 1757-1765.
Harro, et al., Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine, J. of the National Cancer Institute, vol. 93, No. 4, pp. 284-292 (2001).
Moore, et al., Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination, Journal of General Virology 83:2299-2301, (2002).
Palker, et al. “Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles” Vaccine, Butterworth Scientific,—2001, 19(27), pp. 3733-3743.
Reinis, M., Technology Evaluation: HPV Vaccine (Quadrivalent), Aventis Pasteur, Current Opinion in Molecular Therapeutics, vol. 6, No. 2, Apr. 2004, pp. 206-211.
Roden, et al. “Assesment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition” J of Virology, The American Society for Microbiology, 1996, 70(5), pp. 3298-3301.
Schiller et al., Papillomavirus-like particles and HPV vaccine development, Seminars in Cancer Biology, vol. 7, No. 6, pp. 373-382 (1996).
Schiller, et al, Papillomavirus-like particle base vaccines: cervical cancer and beyond, Expert Opinion on Biological Therapy, Ashley, London, GB, vol. 1, No. 4, pp. 571-581 (2001).
Steller, et al., Cervical cancer vaccines: progress and prospects, Journal of the Society for Gynecologic Investigation, US, Sept., Oct. 2002, vol. 9, No. 5, pp. 254-264 (2002).
Thompson, et al , Immunogenicity & reactogenicity of a recombinant HPV6 fusion protein vaccine adjuvanted with monophosphoryl lipid A, Biochemical Society Transactions, vol. 274S p. 25 (1997).
Van Ranst, et al., Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations, J. of General Virology, vol. 73, pp. 2653-2660 (1992).
Villa., et al, A dose-ranging safety and immunogenicity study of a quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine in women, HPV Clinical Workshop & 20thInternational Papillomavirus Conference 2002, Oct. 4-9, 2002, Paris, Institute Pasteur.
Villa et al., “Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) L1 Virus-Like Particle Vaccine

Affiliated with

Also associated with

Rating

Vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4193156